Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tildrakizumab - Almirall/Sun Pharmaceutical Industries

Drug Profile

Tildrakizumab - Almirall/Sun Pharmaceutical Industries

Alternative Names: ILUMETRI; Ilumetri; ILUMYA; MK-3222; SCH-900222; SUNPG 1622; SUNPG 1622 I; SUNPG 1623 I; SUNPG 1623 II; SUNPG 1623 III; SUNPG 1623 IV; SUNPG1623; Tildrakizumab-asmn

Latest Information Update: 15 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Almirall S.A.; China Medical System; Institute of Cancer Research; Merck & Co; Schering-Plough; Sun Pharmaceutical Industries
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-23 subunit p19 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Preregistration Psoriatic arthritis
  • Phase II/III Ankylosing spondylitis; Intervertebral disc degeneration; Non-radiographic axial spondyloarthritis
  • Phase I/II Prostate cancer
  • Discontinued Autoimmune disorders

Most Recent Events

  • 08 Mar 2024 Efficacy and safety data from a phase III trial in Plaque psoriasis presented at the American Academy of Dermatology (AAD-2024)
  • 15 Nov 2023 Sun Pharma and Institute of Cancer Research terminates a Phase-I/II clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom and Switzerland (PO) due to early lack of response outcomes (NCT04458311)
  • 26 May 2023 Registered for Plaque psoriasis in China (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top